

# Gemini Stock Analysis Report

---

Based on the detailed analysis of the **CIPLA.NS** report provided (generated 2026-01-17), here is the assessment.

## Step 1: Audit the Data

- **Data Present:**
  - **Price Action:** Daily and Weekly timeframe charts with candlestick analysis.
  - **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, and Bollinger Bands.
  - **Momentum:** RSI, MACD, and Relative Strength (RS) relative to the Pharma sector.
  - **Volume:** Volume analysis, distribution days, and moving averages.
  - **Fundamentals:** Basic revenue/EPS growth trends and valuations (Forecaster).
- **Data Missing:**
  - **Specific Catalyst:** The report shows a sharp drop but does not specify the fundamental news event (e.g., FDA observation, earnings miss) causing the crash.
  - **Option Chain:** No data on open interest to identify derivative support/resistance levels.
- **Confidence Level: High.** The technical profile is complete enough to make a chart-based decision, despite the lack of news context.

## Step 2: Analyze the Setup

- **Price Structure (Bearish):** The stock has suffered a significant structural breakdown. It has collapsed below a consolidation zone (1500-1600) and is currently at INR 1397.50.
- **Trend (Strong Downtrend):**
  - The stock is trading below all key EMAs (20, 50, 200).
  - **Death Cross:** The 50 EMA (1499) has crossed below the 200 EMA (1506), a major intermediate-term bearish signal.
  - **Supertrend:** Weekly, Daily, and even Monthly indicators are likely red (Daily is confirmed "Sell").
- **Momentum:**
  - **RSI:** Currently at 25.57 (Oversold). While this suggests a potential short-term "dead cat bounce," usually trends do not reverse V-shape from here without a base formation.
  - **Bollinger Bands:** Price is riding down the Lower Band (Band Walk), indicating extreme weakness.
- **Relative Strength:** The RS Score is 47/100, and the stock is labeled "Neutral" but lagging the sector (^CNXPBARMA).
- **Volume:** Significant "Distribution Days" noted in Jan 2026, indicating institutional exit.

**Confluence:** The setup is currently a "Falling Knife." There is no technical confluence to support a long position yet. The "Bullish Breakout" signal on the Volatility Squeeze (Page 14) appears to be a false positive or a misinterpretation of volatility expansion (which happened to the downside).

## Step 3: Formulate the Recommendation

**Decision: NO (Do Not Enter)**

**Reasoning:** Entering now violates risk management principles for intermediate-term trading. The stock has just confirmed a "Death Cross" and broken major support. Buying at 1397 is a gamble on a bounce, not a positional trade. The probability of upside is low until the stock digests the selling pressure and reclaims structural resistance.

# Gemini Stock Analysis Report

---

**Conditional Plan (Watchlist for Reversal):** We require evidence that the selling climax is over and institutional demand has returned.

- **Condition to Buy: A Daily Close above INR 1,480.**
  - *Why:* This level clears the immediate dynamic resistance (EMA 20 at ~1476) and the Supertrend resistance (1470). It signifies that buyers have absorbed the supply and momentum is shifting.
- **Entry Price: INR 1,485** (Limit order upon confirmation of the condition).
- **Stop Loss: INR 1,385** (Daily Close basis).
  - *Why:* This places risk below the current swing low/psychological support of 1400.
- **Take Profit: INR 1,640.**
  - *Why:* This targets the previous breakdown zone and upper resistance range.
  - *Note:* Expect turbulence around INR 1,506 (200 EMA), but if 1480 is cleared, momentum should carry to test the major averages.

**Risk/Reward Ratio:** ~1.5:1 (Acceptable, but not ideal until a base forms).

## News & Analyst Targets

Here is the latest stock research and analysis for **CIPLA Ltd.** for the week ending January 17, 2026.

### 1) Latest News for CIPLA This Week

The most critical development this week concerns a major supply chain disruption for one of CIPLA's key US products.

- **Production Halt of Key US Drug (Lanreotide):** CIPLA announced a temporary pause in the manufacturing of **Lanreotide injection**, a key product for its US business. The halt is at the facility of its partner, **Pharmathen International** in Greece.
- **USFDA Compliance Issues:** The production pause follows an inspection by the USFDA at Pharmathen's facility, which resulted in the issuance of a **Form 483 with nine observations**. These observations cited issues including microbiological contamination and poor aseptic practices.
- **Supply Impact Timeline:** CIPLA expects the re-supply of Lanreotide to resume only in the **first half of FY27** (April-September 2026), creating a significant gap in revenue visibility for the near term.
- **Stock Price Reaction:** Following this news, CIPLA's stock price faced heavy selling pressure, falling approximately **5%** intraday on Friday, January 16, 2026, hitting a 9-month low.

### 2) Brokerage Upgrades & Downgrades

The analyst community has reacted sharply to the Lanreotide news, with a mix of downgrades and target price cuts.

- **Nuvama:** **Downgraded** the stock to "**Reduce**" from "Hold". They cited weak near-term earnings visibility and the risk that CIPLA may not fully recover its market share for Lanreotide even after supply resumes.
- **Morgan Stanley:** Maintained an "**Underweight**" rating. They flagged that the supply disruption, combined with the phase-out of the cancer drug *Revlimid*, will weigh heavily on Q4 FY26 performance.
- **MarketsMojo:** Downgraded the stock rating from "Hold" to "**Sell**" earlier in the period due to weakening technical indicators and flat financial performance.
- **Nomura:** Maintained a "**Buy**" rating (Contrarian View). They believe the negative news is already "priced in" and that the market reaction is excessive.

### 3) Other News Impacting CIPLA

# Gemini Stock Analysis Report

- **Competitor FDA Approvals (Negative Impact):** Competitor **Zydus Lifesciences** received USFDA approval this week for *Eltrombopag* tablets. Additionally, other competitors like Dr. Reddy's and Sun Pharma are awaiting approval for Lanreotide. If they launch during CIPLA's absence, CIPLA risks permanently losing market share.
- **Sector Sentiment:** The Nifty Pharma index has been soft, weighed down by CIPLA's fall. However, the broader IT and banking sectors have outperformed, drawing investor funds away from pharma defensives this week.

## 4) Latest Analyst Targets for CIPLA

Below is the summary of the most recent price targets and ratings issued by major brokerages this week.

Brokerage Firm	Rating	Target Price (INR)	Change	Date of Report
Nomura	Buy	1,770	Maintained	Jan 16, 2026
Jefferies	Hold	1,690	Maintained	Jan 14, 2026
Nuvama	Reduce	1,360	Cut from 1,715	Jan 16, 2026
Morgan Stanley	Underweight	1,292	Cut from 1,396	Jan 16, 2026

**Analyst Note:** The divergence in targets is wide (~37% gap between Nomura and Morgan Stanley), indicating high uncertainty regarding how long the regulatory remediation at the partner facility will actually take. Conservative investors are advised to watch for the next quarterly earnings call for management clarity on the timeline.


# Stock Detailed Analysis Report

**CIPLA.NS**

Current Price: ₹1397.50

Generated: 2026-01-17 18:00

# CIPLA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	6.68%	7.88%
Net Income	Yes	No	27.93%	27.96%
ROE	Yes	No	9.52%	11.86%
EPS	Yes	No	27.89%	27.91%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.63%	0.87%
Net Income	Yes	6.20%	3.79%
ROE	No	-14.71%	-14.71%
EPS	Yes	20.58%	15.61%

# CIPLA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	47.0/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.955 [Neutral]</b>
3M RS:	<b>0.879 [Neutral]</b>
6M RS:	<b>0.951 [Neutral]</b>
1Y RS:	<b>1.010 [Leader]</b>
:	

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	


## SIGNAL CRITERIA::

✓ Emerging RS:	1M (0.955) > 3M (0.879)
✓ Medium-term Lagging:	6M=0.951 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>


# Relative Strength Analysis: CIPLA.NS vs ^CNXPHARMA

## Classification: Neutral


### Price Performance Comparison (Normalized)



### RS Ratio Trends (Multiple Timeframes)



### RS Composite Score Timeline






## CIPLA.NS - EMA Crossover Summary

EMA 20:	1476.55
EMA 50:	1499.16
EMA 200:	1506.90
Trend Status:	<b>Strong Downtrend</b>


CIPLA.NS EMA Crossover Analysis



## CIPLA.NS - Bollinger Bands Summary

Current Price:	1397.50
Upper Band:	1553.00
Middle Band (SMA 20):	1486.50
Lower Band:	1419.99
%B:	-0.1691
Band Width:	0.0895
Status:	Below Lower Band
Signal:	<b>Buy Signal</b>
Recent Signal 1:	<b>Buy Signal at 2026-01-16 00:00:00+05:30</b>


CIPLA.NS Bollinger Bands (20, 2) Analysis



## CIPLA.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	1470.96
Signal Identified On:	2025-10-28


Supertrend Analysis for CIPLA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




# CIPLA.NS - MACD Summary

MACD Line:	-20.41
Signal Line:	-11.30
Histogram:	-9.11
Trend:	<b>Bearish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

CIPLA.NS Price



CIPLA.NS MACD (12, 26, 9)








# CIPLA.NS - Volatility Squeeze Summary

BB Width:	0.0895
ATR:	27.5357
Total Signals:	38
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-0


# CIPLA.NS - Volatility Squeeze Analysis



## CIPLA.NS - RSI-Volume Summary

<b>Current RSI:</b>	25.57
<b>Current Volume:</b>	4333315
<b>Volume MA 20:</b>	1627639
<b>Bullish Divergences:</b>	0
<b>Bearish Divergences:</b>	5
<b>Bearish Div 1:</b>	Date: 2024-10-09 00:00:00+05:30, Price: 1662.74
<b>Bearish Div 2:</b>	Date: 2025-08-25 00:00:00+05:30, Price: 1601.20

# CIPLA.NS RSI-Volume Divergence Analysis



# CIPLA.NS - Volume Analysis



== VOLUME ANALYSIS ==:

Status: 155 Signals Detected

:

2025-12-30 [-]:	Distribution Day
2026-01-08 [-]:	Distribution Day
2026-01-12 [-]:	Distribution Day
2026-01-13 [-]:	Distribution Day
2026-01-14 [-]:	Distribution Day

# CIPLA.NS - Volume Analysis




# Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1524.39	1397.5	2026-01-05
1 Day	DOWNTREND (Sell)	1470.96	1397.5	2025-10-28
15 Min	UPTREND (Buy)	1386.49	1397.8	2026-01-16

# Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bullish	Strengthening	No Signal

CIPLA.NS - 1 Week (Candlestick + EMAs)



CIPLA.NS - 1 Day (Candlestick + EMAs)




CIPLA.NS - 15 Min (Candlestick + EMAs)






Trendlyne Snapshot - CIPLA\_main



Trendlyne Snapshot - CIPLA\_forecaster



Cipla - CIPLA - stock price prediction, stock forecast, target price, analyst ratings from 36 analysts

Cipla has a share price target of Rs 1644, revenue growth forecast of 6.2%, and profit growth estimate of -7.1% for FY26, based on top 36 analyst calls.

Cipla FORECASTER - Analyst Estimates

FORECASTER DASHBOARD

